Dottikon ES Holding Past Earnings Performance
Past criteria checks 2/6
Dottikon ES Holding has been growing earnings at an average annual rate of 26.9%, while the Pharmaceuticals industry saw earnings declining at 2.4% annually. Revenues have been growing at an average rate of 17.5% per year. Dottikon ES Holding's return on equity is 9.1%, and it has net margins of 24.2%.
Key information
26.9%
Earnings growth rate
24.4%
EPS growth rate
Pharmaceuticals Industry Growth | 14.1% |
Revenue growth rate | 17.5% |
Return on equity | 9.1% |
Net Margin | 24.2% |
Next Earnings Update | 29 Nov 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Dottikon ES Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 333 | 81 | 87 | 0 |
31 Dec 23 | 339 | 83 | 87 | 0 |
31 Mar 23 | 326 | 88 | 84 | 0 |
31 Dec 22 | 302 | 81 | 81 | 0 |
30 Sep 22 | 284 | 74 | 78 | 0 |
30 Jun 22 | 268 | 67 | 77 | 0 |
31 Mar 22 | 252 | 59 | 77 | 0 |
31 Dec 21 | 240 | 57 | 77 | 0 |
30 Sep 21 | 229 | 55 | 77 | 0 |
30 Jun 21 | 224 | 54 | 76 | 0 |
31 Mar 21 | 219 | 52 | 75 | 0 |
31 Dec 20 | 204 | 46 | 73 | 0 |
30 Sep 20 | 189 | 39 | 71 | 0 |
30 Jun 20 | 182 | 36 | 70 | 0 |
31 Mar 20 | 175 | 33 | 69 | 0 |
31 Dec 19 | 172 | 31 | 69 | 0 |
30 Sep 19 | 169 | 30 | 69 | 0 |
30 Jun 19 | 158 | 23 | 68 | 0 |
31 Mar 19 | 148 | 16 | 67 | 0 |
31 Dec 18 | 147 | 17 | 66 | 0 |
30 Sep 18 | 145 | 18 | 65 | 0 |
30 Jun 18 | 153 | 22 | 65 | 0 |
31 Mar 18 | 161 | 26 | 64 | 0 |
31 Dec 17 | 159 | 24 | 60 | 0 |
30 Sep 17 | 157 | 22 | 56 | 0 |
30 Jun 17 | 156 | 22 | 55 | 0 |
31 Mar 17 | 155 | 22 | 53 | 0 |
31 Dec 16 | 151 | 22 | 55 | 0 |
30 Sep 16 | 148 | 23 | 57 | 0 |
30 Jun 16 | 136 | 19 | 55 | 0 |
31 Mar 16 | 123 | 14 | 54 | 0 |
31 Dec 15 | 113 | 10 | 52 | 0 |
30 Sep 15 | 102 | 5 | 51 | 0 |
30 Jun 15 | 100 | 3 | 50 | 0 |
31 Mar 15 | 98 | 1 | 48 | 0 |
31 Dec 14 | 95 | 0 | 47 | 0 |
30 Sep 14 | 91 | -1 | 46 | 0 |
30 Jun 14 | 91 | -2 | 46 | 0 |
31 Mar 14 | 92 | -3 | 46 | 0 |
31 Dec 13 | 89 | -5 | 46 | 0 |
Quality Earnings: DESNZ has high quality earnings.
Growing Profit Margin: DESNZ's current net profit margins (24.2%) are lower than last year (26.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DESNZ's earnings have grown significantly by 26.9% per year over the past 5 years.
Accelerating Growth: DESNZ's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DESNZ had negative earnings growth (-8.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (4.5%).
Return on Equity
High ROE: DESNZ's Return on Equity (9.1%) is considered low.